共 50 条
- [21] Safety and efficacy of YBL-006, an anti-PD-1 monoclonal antibody in advanced solid tumors: A phase I study.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Oh, Do-YounPark, John J.Lee, Keun WookKim, Seung TaeSriuranpong, ViroteRha, Sun YoungYoo, ChanghoonKeam, BhumsukSabanathan, DhanushaKim, Se HyunPark, Joon OhParinyanitikul, NapaKim, Min HwanKim, Kyu-PyoKim, MyungsukYoon, JaebongLee, Han SeungOck, Chan-Young
- [22] A phase 1 study of the safety, tolerability, and pharmacokinetics (PK) of MGA012 (anti-PD-1 antibody) in patients with advanced solid tumorsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Lakhani, NehalMehnert, Janice M.Rasco, DrewGordon, MichaelLohr, JoannaPencheva, PepiSharma, SharadLi, HuaLaMotte-Mohs, RossMoore, PaulSun, JichaoSumrow, BradleyWigginton, JonPowderly, John
- [23] PHASE I STUDY OF ONO-4538 (BMS-936558), AN ANTI PD-1 ANTIBODY, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORSANNALS OF ONCOLOGY, 2012, 23 : 159 - 159Yamamoto, N.Yamada, Y.Nokihara, H.Asahina, H.Shibata, T.Tamura, Y.Seki, Y.Honda, K.Tanabe, Y.Tamura, T.
- [24] A phase Ib/II clinical trial of tolerability, safety and efficacy of regorafenib in combination with toripalimab (a PD-1 antibody) in patients with relapsed or metastatic colorectal cancerANNALS OF ONCOLOGY, 2020, 31 : S425 - S425Wang, F.He, M-M.Yao, Y-C.Wang, Z-Q.Jin, Y.Wang, F-H.Qiu, M-Z.Lv, Z-D.Wang, S.Luo, H-Y.Li, Y-H.Zhang, D-S.Xu, R.
- [25] Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I studyEUROPEAN JOURNAL OF CANCER, 2020, 130 : 182 - 192Yang, JianliangDong, LihouYang, ShengHan, XiaohongHan, YingJiang, ShiyuYao, JiaruiZhang, ZhishangZhang, ShuxiangLiu, PengQin, YanWu, HaiFeng, HuiYao, ShengSun, YanSong, HaifengShi, Yuankai
- [26] A phase I/II study to evaluate the safety, pharmacokinetics, and efficacy of PRJ1-3024 in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Zhang, PanpanQin, YanruGong, JifangWang, YongshengYang, KunyuLi, YongshengDai, GuanghaiZhu, JiSha, ShaTong, MingLiao, XuebinShen, Lin
- [27] Safety, PK and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors; Phase 1 StudyANNALS OF ONCOLOGY, 2019, 30Naito, YoichiKuboki, YasutoshiIkeda, MasafumiHarano, KenichiMatsubara, NobuakiToyoizumi, ShigeyukiOishi, MasayoHori, NatsukiNagasawa, TakashiKogawa, Takahiro
- [28] The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II StudyAnnals of Surgical Oncology, 2023, 30 : 7172 - 7180Jia-ying ChenNai-si HuangWen-jun WeiJia-qian HuYi-ming CaoQiang ShenZhong-wu LuYu-long WangYu WangQing-hai Ji
- [29] The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II StudyANNALS OF SURGICAL ONCOLOGY, 2023, 30 (12) : 7172 - 7180Chen, Jia-yingHuang, Nai-siWei, Wen-junHu, Jia-qianCao, Yi-mingShen, QiangLu, Zhong-wuWang, Yu-longWang, YuJi, Qing-hai
- [30] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Falchook, Gerald StevenLoRusso, PatriciaGoldman, Jonathan W.El-Khoueiry, Anthony B.Tolcher, Anthony W.Xing, YanHenry, Jason TimothyKeam, BhumsukKim, Dong-WanKim, Tae-YongKim, Hye RyunHong, Min HeeKim, Min HwanLee, Dae HoLee, SangMiJeon, JuYeunHayslip, John W.Xu, CongGaron, Edward B.